Yes - I saw this, but thanks for posting.
The problem I have with the intentionally misleading announcements is that they are fraudulent. On December 1st, 2016, the company announced that the results to date (cohorts 1 + 2) demonstrate
"Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies"
The CEO further stated that
"The efficacy observed with CLR 131 at the 12.5 and 18.75 mCi/m2 single dose compares favorably to drugs recently approved for relapsed or refractory multiple myeloma."
Now, if you look at recently approved drugs, such as daratumumab, their ORR (which is the FDA's measure of efficacy) is much larger than CLRB's ORR of 0% to date, so that statement is a flat-out lie.
On slide 17 of their BIO CEO 2/13 presentation, the company tried to create the impression that they had PRs, but this slide was - interestingly - removed again from the deck...
News 
Market Data 
Discover 
